AT-003 is an investigational, novel drug being developed for the treatment of Diabetic Retinopathy. AT-003 is part of Applied Therapeutics’ Aldose Reductase Inhibitor (ARI) franchise. The drug inhibits the enzyme Aldose Reductase, which plays a well-established role in the pathogenesis of various conditions, including Diabetic Retinopathy.

AT-007-1005 Clinical Study

Please fill out the form below to view information about AT-007, e.g. a list of contraindicated medications.